Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / GBMA Code of Practice

GBMA Code of Practice

Members of GBMA adhere to a high standard of behaviour and this is formalised via their compliance with the Generics and Biosimilar Medicines Association Code of Practice (Code) introduced 1 March 2010.

In accordance with Code requirements a review of the Code was finalised in December 2020 with the 5th edition of the Code coming into effect in June 2021.

The GBMA Code of Practice is principle based, providing guidance in a single document, on the different legislation, regulation and guidelines with which sponsors of generic medicines listed on the Australian Register of Therapeutic Goods (ARTG) comply.

The GBMA seeks to use all reasonable endeavours to provide healthcare professionals and consumers with a quick, effective and cost free method for redress of potential complaints against a member with regard to breaches of the Code.

Complaints from stakeholders should, in the first instance, be referred back to the respective member who will use all reasonable endeavours to resolve the complaint quickly and effectively. If the stakeholder is not satisfied with the action or decision of the member, the stakeholder may refer the complaint to the GBMA Code Complaint Committee via the GBMA secretariat electronically to barbara.bazarnik@gbma.com.au or by mail to PO Box 87, Deakin West, ACT 2600.

For detailed information on the Code of Practice, please refer to the Code document posted below.

GBMA welcomes and encourages feedback from stakeholders. Feedback can be submitted electronically to admin@gbma.com.au or by mail to PO Box 87, Deakin West, ACT 2600.

 

GBMA Code of Practice 5th Edition

Our Members

logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Peak body for affordable medicines welcomes the announcement of Mark Butler as the new Minister for Health and Aged Care – Prioritising patients is the shared mission

June 1, 2022

Tuesday May 31, 2022 Canberra, ACT The announcement of Australia’s new Health … More...

2022 Biosimilar Awareness Week: 30 May – 3 June

May 30, 2022

Marking a new dawn in medicine choice and affordability #BiosimilarAwarenessWeek2022 Monday May … More...

Health Minister, Greg Hunt MP and Shadow Health Minister, Mark Butler MP both applaud the role of the GBMA Strategic Agreement for the security of the supply of vital medicines

April 1, 2022

Friday March 1, 2022 Canberra, ACT In … More…

© 2022 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us